September 21–23, the 2026 Shenzhen International High-Performance Medical Device Exhibition and Innovative Pharmaceutical Exhibition grandly opened at Hall 1 of the Shenzhen Convention and Exhibition Center (Futian).

This exhibition is hosted by the Shenzhen Medical Device Industry Association and the National High-Performance Medical Device Innovation Center, with the Shenzhen Municipal Development and Reform Commission (Shenzhen Pharmaceutical and Medical Device Industry Office), the Shenzhen Municipal Health Commission, and the Shenzhen Municipal Healthcare Security Bureau as supporting units. It covers all links of the industrial chain, including upstream core components and supply chain support, high-end equipment and innovative drugs and devices, and distribution services and clinical application.

The exhibition features specialized zones such as high-end medical devices, innovative pharmaceuticals, and university/hospital achievement transformation, centrally showcasing Shenzhen's strengths in pharmaceutical and device industry clustering and its momentum for high-quality development. For the first time, an APEC Economies Exchange Zone has been established, highlighting APEC's open characteristics and creating an international exchange window. In parallel, it will focus on two major brand forums plus six major thematic directions, hosting more than 20 professional seminars to deeply discuss cutting-edge industry technologies and market hotspots, and to promote multi-party collaboration among industry, academia, research, medicine, capital, and inspection as well as the co-building of the industrial ecosystem.

01
Policy Frontline Reaches the Booths Directly
Industry Attention Continues to Heat Up

On September 21, Qin Shijie, second-level inspector of the Shenzhen Municipal Development and Reform Commission, attended the exhibition opening ceremony and delivered a speech. He then visited exhibition areas including the National High-Performance Medical Device Innovation Center and the National Biological Manufacturing Industry Innovation Center, learning on site about multiple participating companies' core technology breakthroughs, industrialization progress, and market expansion.

From two national-level innovation platforms to multiple frontline participating companies, this inspection route covered key nodes of industrial chain innovation. The high-performance medical device and biological manufacturing industries are also continuing to receive attention at the industrial policy level, and this attention is moving from scientific research platforms to frontline enterprises, providing a clearer industrial background for the investment institutions and portfolio companies appearing on the same stage.

02
300+ Enterprises on the Same Stage
The Entire Industrial Chain Assembled and Unveiled

With the theme "New Quality Pharmaceuticals and Devices · Intelligence Opens a New Chapter," this exhibition gathered more than 300 participating companies, focusing on fields such as high-end imaging equipment, in vitro diagnostics, rehabilitation medicine, surgical instruments, implantable and interventional consumables, smart healthcare, medical new materials, biopharmaceuticals, and innovative pharmaceuticals, comprehensively covering the entire chain of "technological innovation + clinical research + achievement transformation + industrial landing."

Two national-level platforms, the National High-Performance Medical Device Innovation Center and the National Biological Manufacturing Industry Innovation Center, appeared on the same stage. High-level hospitals in the Greater Bay Area, such as Shenzhen People's Hospital and Peking University Shenzhen Hospital, also brought original projects from the clinical frontline to the exhibition booths. From leading enterprises to emerging players in segmented tracks, from scientific research platforms to clinical institutions, what this exhibition presented was not only the scale of participation, but also a microcosm of complete collaborative coordination across an industrial chain.

03
Efung Capital Appears on the Same Stage
Precise Matching of Industrial Resources

As an investment institution long dedicated to the biopharmaceutical and high-end medical device fields, Efung Capital appeared at this exhibition and engaged in exchanges with upstream and downstream enterprises along the industrial chain as well as clinical institutions.

From early-stage project discovery to post-investment resource matching, Efung Capital's role is not only that of a capital provider, but also a connecting point between portfolio companies and industrial resources.

04
Efung Portfolio Companies Appear at the Exhibition
Concentrated Display to the Industry

During the exhibition, Efung Capital's portfolio companies Pumen Technology, Corecath, Chipscreen Biosciences, HaploX, Core Medical, Innermed, Meichuang Medical, Huamai Medical, Northstar Life, Zifu Medical, and Tuwei Anchuang collectively appeared, presenting through an innovation matrix covering multiple segmented tracks their industrial layout in the biopharmaceutical and high-end medical device fields.

Pumen Technology
Pumen Technology is a high-tech medical device enterprise driven by both R&D and intelligent manufacturing and marketing, a national high-tech enterprise, and a specialized and sophisticated "little giant" enterprise. It is committed to the R&D, manufacturing, global sales, and service of in vitro diagnostics, clinical medicine, dermatological medical aesthetics, and consumer health products.

Chipscreen Biosciences
Chipscreen Biosciences is an original innovative drug enterprise driven by core technologies and building a globally competitive product pipeline. It is China's first original innovative drug enterprise listed on the STAR Market.

HaploX
HaploX is a national high-tech enterprise in tumor liquid biopsy and genetic big data, and a national-level specialized and sophisticated "little giant" enterprise. It has core technological advantages in gene sequencing, liquid biopsy, life information, and big data.

Core Medical

Core Medical was founded in 2016. Its implantable left ventricular assist system Corheart 6 is the world's first artificial heart product to complete CE certification under the EU's new MDR regulatory system, and also China's first and currently only artificial heart product to obtain CE certification.

Innermed

Innermed is a medical device company focused on intracavitary imaging, and has won honors such as national-level specialized and sophisticated enterprise and key little giant. It currently has multiple products on the market, among which its micro-probe ultrasound endoscope ranks among the leading in the industry in market share.

Meichuang Medical

Meichuang Medical is an innovative medical device enterprise focusing on peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance. Its business covers the entire chain of R&D, production and manufacturing, and commercialization of high-end medical devices, and its headquarters is located in Suzhou High-tech Zone, Jiangsu.

Huamai Medical

Huamai Medical is an advanced biotechnology materials and regenerative engineering high-tech enterprise dedicated to human tissue repair and reconstruction. Its headquarters is established in Binjiang District, Hangzhou. It currently has GMP Class 10,000 clean workshops, supporting raw material processing areas, physical and chemical laboratories, testing rooms, and office areas, and possesses large-scale production capacity.

(Some project introductions)

From in vitro diagnostics to regenerative medicine, these enterprises are distributed across different links of the industrial chain, yet jointly point to the same main line: China's high-performance medical devices and innovative pharmaceuticals are moving from single-point technological breakthroughs toward the construction of systematic industrial capabilities. For Efung Capital, moving among these booths is both industrial observation and an extension of post-investment resource matching work.

05
Post-Investment Empowerment Goes Beyond Capital
Accompanying Enterprises Through Key Nodes

Efung Capital's appearance at this exhibition and recommendation of portfolio companies to participate is part of the industrial resource matching in its post-investment management system. Compared with purely financial investment, Efung Capital hopes, through matching resources such as industrial exhibitions, clinical institutions, and upstream and downstream enterprises, to help portfolio companies gain more exposure and cooperation opportunities at key nodes.

Connecting is to help innovation reach clinical application faster; boosting is to help enterprises more steadily navigate cycles. Standing at a new starting point where the new blueprint for pharmaceutical industry development during the 15th Five-Year Plan intersects with the construction of Shenzhen's pharmaceutical and device industry highland, this exhibition is not only a concentrated industrial appearance, but also a full-chain collaborative rehearsal from policy, clinical practice, and technology to capital. In the future, Efung Capital will continue to walk alongside innovative enterprises, serving as a long-termist connector and booster in industrial cycles.

END

[Disclaimer]
The content of this article only represents the views of the Company based on currently publicly available information and materials provided by portfolio companies. It does not constitute any investment advice, medical advice, or guarantee of the performance of any specific enterprise. Investment involves risks, and caution is required when entering the market. Readers should make independent judgments based on public information. Without authorization, reproduction or use for commercial purposes is prohibited.